Mirtazapina Mylan (Mirtazapine)

Mirtazapine works by blocking presynaptic α2‑adrenergic receptors, which increases the release of norepinephrine, and by antagonising postsynaptic 5‑HT2 and 5‑HT3 receptors, thereby boosting serotonergic activity. Its additional H1‑histamine blockade contributes to its sedative effect.

The appropriate dose of Mirtazapina Mylan is determined by the prescribing clinician based on the patient’s clinical condition, response, and tolerability. Dosage adjustments may be needed for elderly patients or those with hepatic or renal impairment.

Safety data for mirtazapine in pregnancy and lactation are limited. It should only be used when the potential benefit justifies the potential risk to the fetus or infant, and clinicians should discuss alternatives and monitoring strategies with the patient.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Compared with selective serotonin reuptake inhibitors (SSRIs), mirtazapine offers a distinct mechanism that can be beneficial for patients with insomnia or poor appetite. It may cause more sedation but less sexual dysfunction, making it a useful alternative when SSRIs are not well tolerated.

Mirtazapina Mylan should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

The medication is taken orally, usually once daily in the evening to take advantage of its sedative effect. It should be swallowed whole with water and not crushed or chewed unless otherwise directed by a healthcare professional.

Serious risks include agranulocytosis, severe hepatic dysfunction, seizures, and rare hypersensitivity reactions such as Stevens‑Johnson syndrome. Patients should be monitored for signs of infection, liver injury, or unusual skin reactions, and the drug should be discontinued if these occur.

Mirtazapina Mylan is contraindicated in patients who have taken monoamine oxidase inhibitors within the past 14 days, those with known hypersensitivity to mirtazapine, and individuals with severe hepatic impairment where the drug cannot be safely metabolised.